American Resources’ (Nasdaq: AREC) subsidiary American Carbon Corporation, an owner and operator of low-cost, high-quality metallurgical and specialty carbon assets, has acquired a 51% ownership interest in a diversified mineral asset with a focus on iron ore, titanium and vanadium with an initial estimated deposit of 212,925,000 tons of raw feedstock with an estimated 106,462,500 tons of ore body, based on an average of 50% magnetic material.

Royalty Management Holding Co. (Nasdaq: RMCO), an innovative royalty company building shareholder value by acquiring and developing high value assets in sustainable market environments, announced that it has acquired a perpetual royalty stream linked to a deposit of high value, diversified natural resources, based in the country of Jamaica, with an initial focus on the permitting, production, and sale of Titanium Dioxide, Iron Ore and Vanadium.

60 Degrees Pharmaceuticals (Nasdaq: SXTP), a pharmaceutical company focused on developing new medicines for infectious diseases, announced it has appointed Kristen Landon to the newly created role of Chief Commercial Officer, effective immediately. Ms. Landon is an accomplished commercial leader with over 26 years’ experience launching, building, and transforming commercial teams and brands in the pharmaceutical industry. “We screened hundreds of applicants during the second half of 2023 and Kristen’s vision and directly relevant experience made her the ideal match for the position,” said Geoff Dow, PhD., 60 Degrees Pharma Chief Executive Officer. “With this hire and last month’s financing, management and the Board are excited about the milestones we aim to achieve in the coming quarters.”

Reviva Pharmaceuticals (Nasdaq: RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, announced that it will host a key opinion leader (KOL) event on Thursday, February 15, 2024 at 12:00 PM ET, featuring Larry Ereshefsky, PharmD, BCPP (Retired professor of Psychiatry, Pharmacology and Psychiatry, The University of Texas; Chief Scientific Officer, Owner, Follow the Molecule LLC) and Mark Opler, PhD, MPH (Chief Research Officer at WCG Inc., Executive Director of the PANSS Institute), who will discuss the unmet medical need and current treatment landscape for patients suffering from acute to chronic symptoms of schizophrenia, and brilaroxazine (RP5063), a next-generation serotonin/dopamine modulator, as a potential treatment.